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Effect of diabetes and peritonitis on the peritoneal equilibration test.
Peritoneal equilibration tests (PET) were performed on 47 patients (15
diabetics) who had been on CAPD for 1 to 112 months. Among new
patients on CAPD (1 to 3 months) with no history of peritonitis, diabetics
had higher D/Pr than non-diabetics (P < 0.02). However, after 7
months of CAPD, in patients with 2 episodes of peritonitis, glucose and
creatinine transport rates were lower (P < 0.05) in diabetic than non-
diabetic patients. Among patients on CAPD for 7 months, creatinine (P
< 0.05) and glucose transport (P < 0.01) were higher in patients with a
history of 3 episodes of peritonitis than in those with 2 episodes. Drain
volumes did not differ between any of the subgroups (all P > 0.05). The
observations in patients newly established on CAPD were substantiated in
a larger study of 55 non-diabetic and 35 non-insulin dependent diabetic
patients. DID0 glucose correlated with plasma glucose (r = 0.40, P < 0.02)
in the diabetic group. Net ultrafiltration was reduced in hyperglycemic (P
= 0.022) but not normoglycemic diabetics (non-diabetics 231 167 ml,
hyperglycemic diabetics 127 177 ml, normoglycemic diabetics 238 159
ml). Creatinine clearance was higher in normoglycemic (P 0.02) but not
hyperglycemic diabetics (non-diabetics 6.8 0.9 mI/mm, hyperglycemic
diabetics 6.9 0.8 mI/mm, normoglycemic diabetics 7.4 0.7 mi/mm).
These data show that diabetes and peritonitis incidence should be borne
in mind when interpreting results of the PET. We conclude that peritoneal
membrane transport differs in non-insulin dependent diabetic patients and
that ultrafiltration will be lower than is achievable in non-diabetic patients
with the same glucose transport rate unless normoglycemia is maintained.
The peritoneal transport rate is an important factor in deter-
mining a patient's response to peritoneal dialysis [1]. The perito-
neal equilibration test (PET), first proposed by Twardowski et a!
[2], enables simple, quantitative measurement of peritoneal trans-
port and ultrafiltration in patients on peritoneal dialysis. Creati-
nine and glucose transport are measured in timed dialysate and
plasma samples under standardized conditions and the transport
rates and drain volume interpreted in relation to published ranges
[3]. Transport rates of creatinine and glucose are expressed as a
dialysate-to-plasma ratio in the case of creatinine (D/PCI) and a
dialysate-to-dialysate at time zero ratio in the case of glucose
(D/D0). Patients were categorized as either low, low-average,
high-average or high transporters. Low-average and high-average
transporters lie within one standard deviation of the mean,
whereas low and high transporters lie outside these ranges.
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Patients with high peritoneal solute transport are likely to have
inadequate ultrafiltration on standard continuous ambulatory
peritoneal dialysis (CAPD) and may do better on dialysis regimes
utilizing short dwell exchanges, such as can be achieved with
nightly intermittent peritoneal dialysis [3, 4] or continuous cyclic
peritoneal dialysis [5]. Less commonly, low transport states occur
[4] associated with symptoms and signs of inadequate dialysis.
These patients may be better treated with high flow peritoneal
dialysis or transferred to hemodialysis [3]. High-average trans-
porters appear to have few problems on standard CAPD whereas
those of low-average may require an increase in their dialysis as
their residual renal function declines [3].
Initial assessment of patients with a PET has been proposed as
a means of predicting response to standard CAPD [2]. Addition-
ally, comparison of repeat PET's with the baseline value is useful
in the differential diagnosis of problems such as inadequate
dialysis, ultrafiltration failure, dialysate leaks, catheter malposi-
tion, peritoneal adhesions, mesothelial alterations, non-compli-
ance [2, 31, and also in establishing whether low serum creatinine
is due to good dialysis or poor nutrition.
To date, only limited data for interpretation of the PET have
been published: the initial study of Twardowski et al [2] estab-
lished ranges on a North American CAPD population which have
recently been largely verified in the UK [5]. However, neither of
these studies attempted to assess the effects of diabetes and
peritonitis on the outcome of the PET. In the present study PET
results in a CAPD population have been studied in relation to
these important clinical parameters.
Methods
Patients
Initial study group. PET's were performed on 47 informed
patients attending the Renal Dialysis Unit. All patients had been
established on CAPD for at least one month and were not studied
within one month of an episode of peritonitis. Patients were
subdivided into four groups depending on treatment duration,
presence or absence of diabetes and previous number of perito-
nitis episodes (Table 1). To distinguish relapse and reinfection,
episodes of peritonitis were separated by at least two weeks [6].
Extended study group. Standard PET's were performed on 55
non-diabetic patients (34 male, 21 female, mean age 55 years) and
on 35 patients with non-insulin dependent diabetes (22 male, 13
female, mean age 60 years). All patients were recently established
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Table 1. Clinical details of patients on whom peritoneal equilibration tests were performed in the initial study group
Age
Months
on
Episodes
of
(years)/sex CAPD peritonitis Cause of renal failure
Group 1. Non-diabetic patients on CAPD for 1—3 months with no episodes of peritonitis (N = 15)
1. 49/M 2 0
2. 43/M 1 0
3. 44/M 2 0
4. 45/F 1 0
5. 55/M 1 0
6. 55/M 2 0
7. 62/M 2 0
8. 58/F 1 0
9. 26/M 2 0
10. 71/F 3 0
11. 70/M 3 0
12. 66/F 1 0
13. 58/F 3 0
14. 42/F 3 0
15. 76/F 2 0
Group 2. Diabetic patients on CAPD for 1—3 months with no episodes of peritonitis (N = 6)
16. 63/F 2 0
17. 57/F 2 0
18. 65/F 1 0
19. 62/M 1 0
20. 69/F 3 0
21. 48/M 2 0
Group 3. Patients on CAPD for  7 months with 2 episodes of peritonitis (N = 13)
22. 18/F 18 1
23. 51/M 57 2
24. 56/F 26 1
25. 70/M 8 0
26. 27/M 23 2
27. 75/M 15 1
28. 60/F 8 1
29. 61/M 7 1
30. 40/M 7 0
31. 64/M 7 1
32. 66/F 18 0
33. 67/M 21 2
34. 70/M 19 1
Group 4. Patients on CAPD for  7 months with  3 episodes of peritonitis (N = 13)
35. 34/M 18 3
36. 36/M 66 7
37. 44/M 21 3
38. 27/M 26 3
39. 63/M 27 3
40. 73/M 112 5
41. 50/M 42 4
42. 55/M 45 6
43. 48/F 43 5
44. 75/F 63 5
45. 56/F 95 4
46. 48/M 26 4
47. 54/F 11 3
Abbreviations are: CAPD, continuous ambulatory peritoneal dialysis; GN, glomerulonephritis; SLE, systemic lupus erythematosus; IDDM,
insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus.
unknown
unknown
unknown
polycystic kidney disease
cystinuria
hypertensive renal disease
hypertensive renal disease
reflux nephropathy
chronic GN
hypertensive renal disease
unknown
hypertensive renal disease
reflux nephropathy
unknown
neuropathic bladder
unknown (NIDDM)
diabetic nephropathy (NIDDM)
diabetic nephropathy (NIDDM)
diabetic nephropathy (NIDDM)
diabetic nephropathy (NIDDM)
diabetic nephropathy (NIDDM)
SLE nephritis
focal GN
chronic GN
unknown
unknown
obstructive nephropathy
diabetic nephropathy (NIDDM)
diabetic nephropathy (NIDDM)
diabetic nephropathy (LDDM)
diabetic nephropathy (NIDDM)
diabetic nephropathy (NIDDM)
chronic GN (NIDDM)
diabetic nephropathy (NIDDM)
chronic GN
chronic GN
polyarteritis nodosa
hypertensive renal disease
hypertensive renal disease
chronic GN
chronic GN
tubulointerstitial disease
hypertensive renal disease
unknown
chronic GN
diabetic nephropathy (IDDM)
diabetic nephropathy (NIDDM)
on CAPD (3 to 14 weeks) and had no history of peritonitis. Net
ultrafiltration (ml) was calculated as the difference between
drained volume and instilled volume (2000 ml).
Test protocol
PET's were performed according to a standardized procedure
(Peritoneal Equilibration Test Procedure Guide. Egham, Baxter
Healthcare Ltd., Norfolk, UK, 1990). Patients came to the Renal
Unit in the morning, having had their overnight dialysate in situ
for 8 to 12 hours. The overnight dwell was drained for 20 minutes,
whether or not it was complete, with the patient in a sitting
position. A 2 liter 2.27% DianealTM Bag (Baxter Healthcare Ltd.)
was then infused at a rate of 200 mI/mm (total infusion time 10
mm) with the patient in a supine position. During this procedure
patients were rolled from side to side after each 400 ml to ensure
adequate mixing of fresh solution with residual dialysate. Zero
dwell time (0 hr) was taken as the time at completion of infusion.
The 0 hour dialysate sample was immediately taken by draining
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Fig. 1. Interference of glucose in the Jaffe rate creatinine method. A
creatinine standard (8840 jmo1/1iter) was diluted into the range 50 to 500
smol/liter in either normal saline (lower line) or 2.27% dialysis fluid
(upper line).
approximately 200 ml dialysate back into the bag, mixing, and
removing 10 ml via the sample port under sterile conditions. The
remaining 190 ml was then reinfused into the patient. A further
sample was taken after two hours together with a 10 ml blood
sample, 1 ml of which was placed in a tube containing fluoride as
preservative for glucose analysis. The remainder was allowed to
clot before being centrifuged and the serum saved. After four
hours the dialysate was drained over a 20 minute period, again
with the patient in a sitting position. An aliquot (10 ml) of this was
saved and the final drain volume recorded. Patients continued
with their normal level of physical activity during the test.
Dialysate samples for glucose analysis were immediately diluted
tenfold in sterile normal saline and sent to the laboratory in tubes
containing fluoride as preservative. Aliquots of dialysate and serum
samples were stored at —20°C prior to measurement of creatinine.
Glucose was measured by a glucose oxidase-peroxidase method
(Glu-Cinet; Sciavo Diagnostics Inc., Wayne, NJ, USA) on an Epos
analyser (BDH/Merck Diagnostics Division, Poole, Dorset UK) and
creatinine by a Jaffe rate method (Beckman Creatinine Analyser 2,
Beckman Instruments Ltd., Bucks, UK).
Determination of a correction factor for glucose inteiference in the
creatinine assay
Glucose is known to interfere in the Jaffe reaction [71. A
correction factor (K) was determined by diluting a creatinine
standard (8840 mol/liter, Beckman Instruments Ltd.) into the
range 50 to 500 jimol/liter in both normal saline and 2.27%
dialysis fluid, Following assay a correction factor was derived from
the equation
K1lucose],te measured[creatinine]te
— measured[creatinine]e
Glucose
oxidase
/peroxidase
Glucose
oxidase-02
electrode
Glucose
dehydrogenase Hexokinase
0 hr 119.3 (1.00) 115.0 (1.00) 116.3 (1.00) 109.8 (1.00)
2 hr 56.8 (0.48) 53.8 (0.47) 55.8 (0.48) 45.0 (0.41)
4 hr 34.8 (0.29) 34.7 (0.30) 34.0 (0.29) 25.3 (0.23)
Comparison of glucose methods in dialysate
The effect of different assays for glucose was studied by
measuring glucose in 18 dialysate samples (6 each of the 0, 2 and
4 hr samples) by four different methods: (1) the glucose oxidase-
peroxidase method above; (2) glucose oxidase with an oxygen
electrode (Beckman Glucose Analyser 2); (3) glucose dehydroge-
nase (Ens analyser using BDHIMerck reagents, catalog no. 19
700); and (4) hexokinase (Epos analyser using reagents from
Boehringer Mannheim Ltd., East Sussex, UK, catalog no. 263
826). Samples were all diluted tenfold in normal saline. An
identical calibrant (Nycomed-ASTM; Nycomed Ltd., Birmingham,
UK) was used throughout.
Results
Analytical methods
The correction factor for glucose interference in the creatinine
assay varied depending on the creatinine concentration, ranging
from 0.41 at 50 Lmol/liter to 0,28 at 450 smolIliter (Fig. 1). The
average value of 0.36 was used to correct the measured creatinine
concentration.
Mean glucose concentrations for the six patients at 0, 2 and 4
hours are shown in Table 2. The glucose method used had a
significant effect on the result (Friedman's two-way analysis of
variance; xr2 = 355, P < 0.001), the glucose oxidase-peroxidase
method giving significantly higher values and the hexokinase
method significantly lower values compared with the other three
(Wilcoxon's matched-pairs signed-rank test, P < 0.01 in all cases).
The glucose oxidase/oxygen electrode and glucose dehydrogenase
methods did not give significantly different results for glucose
concentration (Wilcoxon's matched-pairs signed-rank test, P >
0.05). The glucose method also had a significant effect on two and
four hour D/DO ratios (Friedman's two-way analysis of variance;
= 22, P < 0.001): this was attributable to the significantly
lower ratios observed with the hexokinase method (Wilcoxon's
matched-pairs signed-rank test, P < 0.01). DID0 ratios did not
differ between the glucose oxidase-peroxidase, glucose oxidasel
oxygen electrode and glucose dehydrogenase methods (Wilcox-
on's matched-pairs signed-rank test, P > 0.05). The routine
laboratory glucose oxidase-peroxidase method was used for all
patient sample analyses.
Initial study group
Among the CAPD population as a whole DIPc, D/D0 and
drain volume were normally distributed ( goodness-of-fit test,
P > 0.05). There was a strong association between four hour
D/Pcr and four hour D/D0 (r =
—0.872,P < 0.001, Fig. 2) but only
0
E:i
a)
C
a)0
a)
U,
a)
Table 2. Mean glucose concentrations (mmollliter) measured by four
methods in six dialysate samples at 0, 2 and 4 hours after starting
the PET
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Dialysate glucose/initial dialysate glucose concentration ratios (DID0)
are given in parentheses.
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weakly significant correlations between drain volume and four
hour D/Pc. or four hour DID0 (r = —0.292 and r = 0.319,
respectively, P < 0.05 in both cases). Transport rates of creatinine
and glucose in our CAPD population were significantly faster than
those originally described by Twardowski, Khanna and Noiph [31
and drain volumes were lower (Table 3 and Figs. 3 to 5). To
elucidate why this might be, the patients were subdivided accord-
ing to length of therapy, presence of diabetes and peritonitis
incidence.
Amongst new patients on CAPD (1 to 3 months) with no
episodes of peritonitis, diabetics had higher DIPCr than non-
diabetics (P < 0.02, Fig. 3, Table 4). Glucose transport rate was
also higher in the diabetics (that is, lower DID0) although this
failed to reach significance (P = 0.07; Fig. 4 and Table 4).
However, after 7 months of CAPD, in patients with 2 episodes
of peritonitis, glucose and creatinine transport rates were lower (P
< 0.05) in diabetic than non-diabetic patients (Table 4). Final
drain volumes did not differ between either new or established
diabetic and non-diabetic patients (P > 0.05; Mann-Whitney
U-test used for all comparisons).
Among patients established on CAPD for 7 months, creati-
nine (P < 0.05) and glucose transport (P < 0.01) were higher in
patients with a history of 3 episodes of peritonitis than in those
with 2 episodes (Table 4). However, if diabetic patients were
excluded from these groups, then only D/PC. remained signifi-
cantly different (P < 0.05). Neither D/PCr nor D/D0 in either of
the established groups differed significantly from the new non-
diabetic patients (P> 0.05). Drain volumes did not differ between
established patients with a low and high incidence of peritonitis (P
> 0.05, Fig. 5) and neither of these groups differed from new
non-diabetic patients (P> 0.05, Mann-Whitney U-test used for all
comparisons).
Variability in four hour DIPCr was greatest in new patients and
in established patients with a high incidence of peritonitis. In
established patients with a low incidence of peritonitis, all results
were within one standard deviation of the mean (Fig. 6).
Twardowski et a! [31 Present study
N (tests) 103 47
N (patients) 86 47
N (diabetics) 18 15
Age years 19—84 18—76
CAPD months 0.1—84 1—112
DID0 2hr
D/DO 4 hr
D/Pcr 0 hr
D/P, 2 hr
D/Pcr 4 hr
Volume ml
0.55 0.11 (0.78—0.24)
0.38 0.11 (0.61—0.12
0.07 0.05 (—0.0 1—0.24)
0.48 0.14 (0.23—0.87)
0.65 0.16 (0.34—1.03)
2368 283 (1580—3226)
0.53 0.08 (0.70_0.35)a
0.32 0.08 (0.52—0.16)"
0.10 0.04 (003023)"
0.54 0.12 (0.29 —0.84)"
0.75 0.11 (0.47_0.98)"
2235 253 (1420—2610)"
Extended study group
To investigate the differences found between diabetic and
non-diabetic patients new to CAPD in the initial group, the study
was extended to include a larger population. The results are
shown in Table 5. Plasma glucose and creatinine transport were
significantly higher in the diabetic group as a whole whereas
glucose transport, ultrafiltration volume and creatinine clearance
did not differ. In the diabetic group, glucose transport correlated
with plasma glucose (4 hr DIDO glucose = 0.236 + 0.007 plasma
glucose, r = 0.40, P < 0.02) but creatinine transport and volume
of ultrafiltrate did not.
To elucidate the influence of plasma glucose on the PET, the
diabetic patients were subdivided according to whether the two-
hour plasma glucose concentration was 'high' (plasma glucose
>8.7 mmollliter, N = 23) or 'normal' (plasma glucose <8.7
mmollliter, N = 12, not significantly different from the non-
diabetic group). This revealed that ultrafiltration volume was
significantly lower in hyperglycemic diabetics than in non-diabetic
patients whereas it was no different in normoglycemic diabetics.
Creatinine transport remained higher in the diabetic subgroups
compared with the non-diabetic patients, and glucose transport
did not differ, although it tended to be higher (lower D/D0) in the
normoglycemic group. Creatinine clearance was significantly
higher in the normoglycemic diabetics than in the non-diabetic
patients but was no different in the hyperglycemic group.
Discussion
Generally glucose and creatinine transport across the perito-
neal membrane will mirror each other, and this is confirmed by
the strong association between four hour D/PCr and D/D0 in the
present and earlier studies [3, 5]. The poorer correlation observed
between transport rates and drain volume in all of these studies is
probably because factors other than glucose transport are also
important in determining ultrafiltration rate [21. Drain volume is
not only determined by ultrafiltration rate but is also affected by
lymphatic reabsorption rate [81, dialysate leakage and incomplete
drainage [2].
Solute transport was higher than previously described [2, 3, 5]
and drain volume lower. Applying published [3] ranges for
interpretation, transport would be classified as above average in
0.50
a)
Co0
0.40
0)0
0.30
0
0.20
Table 3. Comparison of transport and patient characteristics with those
of a published study
0.5 0.6 0.7 0.8
4 hour D/P creatinine
Fig. 2. Relationship between 4 hour glucose (DID0) and 4 hour creatinine
(DIP,.) transport in the peritoneal equilibration test. Diabetic patients are
represented by open symbols and non-diabetic patients by closed symbols.
r = —0.872; P < 0.001; D/D0 glucose = 0.802 — 0.641 (D/P creatinine).
0.9 Transport results are expressed as mean SD (range).
Statistical comparisons were performed using the unpaired t-test.
a p> 0.05 compared to Twardowski et a! [3]
"P < 0.01 compared to Twardowski et a! [3]
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Fig. 3. Comparison of 4 hour DIPn ranges
derived by Twardowski et at [3] with those
derived from the current study. Individual results
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subgroups are plotted twice; on the left they are
superimposed on the ranges derived by
Twardowski et a!, on the right they are shown
with their derived ranges. Diabetic patients are
represented by open symbols and non-diabetic
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89% and 79% of our patients using four hour D/Pr and DID0,
respectively; drain volume would be below average in 73%, with
net ultrafiltration being on average about 150 ml per exchange
lower than that of Twardowski's patients. Use of these ranges
would suggest that the vast majority of our patients have above
average transport rates, and approximately one third would be
classified as high transporters. This would predict a high incidence
of ultrafiltration problems in our patient population, a suggestion
not borne out by clinical experience.
Findings may differ from those of others [2, 5] due to a
combination of effects of analytical variation and patient charac-
teristics. The hexokinase method for glucose determination has
recently been recommended as the method of choice in peritoneal
dialysis fluid [1], since it suffers least from analytical interference
[9]. However, it is not routinely used in many laboratories. Lower
Fig. 4. Comparison of 4 hour DID0 ranges
derived by Twardowski et at [3] with those
derived from the Current study. Individual results
for all patients combined and for the four
patient groups are plotted twice; on the left
they are superimposed on the ranges derived by
Twardowski et al, on the right they are shown
with their derived ranges. Diabetic patients are
represented by open symbols and non-diabetic
patients by closed symbols.
measured glucose concentrations as a result of assay by the
hexokinase method resulted in slightly lower DIDO ratios. There-
fore, had this method been used by us, the difference between the
ratios in the present study and that of Twardowski et a! would
have been even greater.
Subtle variations in the Jaffe reaction methodology and the
correction factor used may have caused slight differences in results
between studies. The correction factor differed from that of
Twardowski et al [2] but was in broad agreement with that of
others [10, 11]. These latter authors also found the degree of
interference to vary depending on the level of creatinine being
measured, and an equation has been derived to adjust for this
[11]. However, the correction factor has a minimal effect on
D/Pcr, especially at four hours, when the creatinine concentration
is high and the glucose concentration is low; practical experience
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Table 4. Transport characteristics and drain volume for the patient groups and subgroups in the initial study
Patient groups and subgroup
Episodes of
peritonitis
D/Pr
4 hr
D/DO
4 hr
Drain volume
ml
New patients
Group 1. Non-diabetic (N 0 0.720 (0.47—0.93) 0.330 (0.20—0.51) 2210 (1920—2540)
= 15)
Group 2. Diabetic (N = 6) 0 0.835 (0.76—0.98) 0.245 (0.16—0.37) 2100 (1880—2490)
Established patients
Group 3. All (N = 13)  2 0.700 (0.65—0.79) 0.370 (0.29—0.44) 2380 (1420—2610)
Non-diabetic (N = 6) 2 0.720 (0.69—0.79) 0.345 (0.29—0.38) 2390 (1420—2570)
Diabetic (N = 7) 2 0.670 (0.65-.-0.71) 0.400 (0.35—0.44) 2340 (1910—2610)
Group 4. All (N = 13) 3—7 0.770 (0.47—0.97) 0.310 (0.20—0.52) 2290 (1900—2600)
Non-diabetic (N = 11) 3—7 0.770 (0.47—0.97) 0.310 (0.20—0.52) 2300 (1900—2600)
Groups 1 to 4 are defined in Table 1. Results are shown as median (range).
showed use of an average correction factor derived specifically for
this method to be adequate.
The age range and treatment duration of the patients are
similar to those in the study of Twardowski et al [2], although the
present study had a higher percentage of diabetics. The preva-
lence of diabetes in the study of Davies et al [5] was not stated.
Peritonitis history influences transport (vide infra), but its effect on
outcome of the PET in earlier studies [2, 5] was not examined.
Additionally, the previous studies used some patients twice in
determining the ranges, which may have biased results. Factors
known to affect peritoneal transport, such as patient size and
weight [12, 5], mobility during the test [4], and the nature of the
underlying disease [13] may have differed between the studies.
Transport rates in diabetic patients newly established on CAPD
were higher than those of an equivalent group of non-diabetic
patients, but this difference was reversed in diabetics established
on CAPD for seven or more months. Since this was a cross
sectional study, it is possible that high transporters may have been
selected out from the established group, due to their unsuitability
0246 01o12141o1t2022242625204050e070809010011012n
Time, months on CAPD
Fig. 6. Relationship between 4 hour D/P0 and time on CAPD. Horizontal
lines represent mean so. Diabetic patients are represented by open
symbols and non-diabetic patients by closed symbols. Circular symbols
represent new patients, triangular symbols patients who have been on
CAPD for 7 months with 2 episodes of peritonitis and square symbols
patients who have been on CAPD for 7 months with >2 episodes of
peritonitis.
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Table 5. Comparative PET data from non-diabetic and non-insulin dependent diabetic patients new to CAPD in the extended study group
Non-insulin dependent diabetics
Plasma glucose >8.7 Plasma glucose <8.7
.Non-diabetics
N=55
All
N=35
mmol/liter mmol/liter
N=23 N=12
Plasma glucose mmol/l 5.8 1.1 (4.2—8.7) 11.3 5.0 (2.6—21.8) 13.9 4.1 (8.9—21.8) 6.3 1.5 (2.6—8.4)
P 0.000 0.000 NS
4 hr D/Pcr 0.74 0.10 (0.47—0.94) 0.79 0.09 (0.64—0.98) 0.78 0.09 (0.64—0.98) 0.80 0.08 (0.66—0.93)
P 0.015 0.057 0.045
4 hr DID0 glucose 0.33 0.08 (0.19—0.51) 0.31 0.08 (0.15—0.45) 0.33 0.08 (0.16—0.45) 0.28 0.08 (0.15—0.41)
P NS NS NS
Net volume of ultrafiltrate 231 167 (—120—540) 165 177 (—170—560) 127 177 (—170—415) 238 159 (—40—560)
ml, P NS 0.022 NS
Creatinine clearance mI/mm 6.8 0.9 (4.5—9.2) 7.1 0.8 (5.7—8.7) 6.9 0.8 (5.7—8.5) 7.4 0.7 (6.3—8.7)
P NS NS 0.020
Data shown as mean SD (range). P values (unpaired t-test) vs. non-diabetic group. NS is not significant.
for standard CAPD. Twardowski et a! [2] observed that patients
with transport rates more than one standard deviation from the
mean were unlikely to remain on standard CAPD after 20 months
of treatment. Rapid transport in diabetic patients commencing on
a CAPD programme may reflect their known increased capillary
permeability [14] although a greater effective surface area cannot
be excluded. Twardowski et al [2] also reported higher transport
rates in diabetic patients, but did not state how long these patients
had been on CAPD.
In diabetic rats [15], increased peritoneal permeability to low
Mr solutes was associated with decreased ultrafiltration. In the
present study, it is clear that while diabetesperse affects creatinine
transport, the prevailing blood glucose concentration affects ul-
trafiltration volume and creatinine clearance. At the same level of
glucose transport, the mean volume of ultrafiltrate was 45% lower
in hyperglycemic diabetics than in non-diabetic patients, possibly
because of the opposing osmotic effects of plasma glucose. Since
creatinine transport was higher in diabetic patients new to CAPD
than in non-diabetic patients, it was expected that glucose trans-
port would also be higher (that is, lower DID0), but it was not.
This was most likely due to the effect of the higher plasma glucose
maintaining a higher DID0 glucose ratio and is also supported by
the finding that glucose transport tended to be lower in the
'normoglycemic' diabetic patients.
The higher creatinine transport rate in diabetics was reflected
as a higher creatinine clearance only in the normoglycemic
subgroup since only in this group was ultrafiltration maintained.
Thus hyperglycemia, by impairing ultrafiltration, also abolishes
the increase in creatinine clearance that might otherwise be
expected in diabetes. Previous studies have yielded conflicting
data on the effects of diabetes on solute transport and clearance
across the peritoneal membrane [16—18]; however, plasma glu-
cose was not taken into account which may explain the lack of
consensus.
Peritonitis has been shown to acutely increase solute transport
and decrease ultrafiltration [19], but it has been assumed that this
is corrected within three weeks of treatment [19]. It was unex-
pected, therefore, to find that transport was higher in patients
with a strong history of peritonitis than in an equivalent group of
patients with a low peritonitis incidence. However, transport rates
in both of these established groups did not differ significantly from
those in non-diabetic patients recently started on CAPD. The new
patient group contained a number of high and low transporters
who may ultimately be unsuitable for standard CAPD [2], ac-
counting for the lack of difference between new and established
patients in this cross sectional study. Although the number of
patients in our study was relatively small, the results are consistent
with a longitudinal study [5] showing that, in some patients, large
increases in D/Pr were associated with previously prolonged
episodes of peritonitis.
It is difficult to define the best patient group from which to
derive reference ranges for the PET. Ranges derived using new
patients are likely to be broad since they will include patients
ultimately unsuitable for standard CAPD. Ranges derived from
patients established on CAPD may better reflect the limits of
acceptable membrane characteristics and may therefore be nar-
rower, but this will depend on the historical incidence of perito-
nitis. Twardowski et a! [2] found less variability in four hour D/Pr
in patients successfully established on CAPD than in new patients.
The method of deriving ranges used by Twardowski et al and in
the current study (that is, using a large unselected patient group
and calculating the mean, SD and range) may represent an
acceptable compromise but is likely to result in differences
between centers depending on the patients included. For example,
Davies et a! [5] found D/Pr to be higher and drain volume lower
in an unselected group than in a group comprising new patients
and established well patients.
The PET provides a simple, quantitative assessment of perito-
neal membrane function in patients on CAPD, which may be of
prescriptive, prognostic and diagnostic value. However, our data
suggest that Renal Units should establish reference ranges from
defined patient groups appropriate to their own CAPD popula-
tion and laboratory methods, bearing in mind the possible effects
of diabetes and peritonitis on the outcome of the test. Ultrafiltra-
tion in diabetic patients is reduced in the presence of even
moderate hyperglycemia, which may compromise fluid balance
and solute clearance in this group, especially once residual renal
function has declined.
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